Contipharma has just developed a new generation of diagnostic test: a major breakthrough in the fight against epidemics!
After malaria, Contipharma continues to innovate with the development of a test that combines both the sensitivity and specificity qualities of a PCR test and the rapidity of an antigen test; this is a first in the field.
The first application of this major innovation is the development of a test to detect monkeypox, which severely affects the DRC and whose Ib strain, more virulent according to the WHO, is now also spreading in Western countries. The WHO is even sounding the alarm about it.
